Pharmaceutical companies are currently granted at least eight years’ “protection” over their data from research and clinical ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 ...

In this week’s edition of InnovationRx, we look at the policy uncertainty around vaccines, sex differences in GLP-1 drug side ...

To stand out in the 2025 job market, personalize cover letters, focus on tangible achievements, and maintain authenticity while engaging recruiters through concise and impactful content. Adapt your ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday ...

“I thought we’d sell a few instruments every year but that’s not enough to cover costs and return ... support of global pharmaceutical giant AstraZeneca. “We were a bit lucky in that ...

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...